Billiontoone (NASDAQ:BLLN) Trading Down 5.8% - What's Next?

Shares of Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) were down 5.8% during trading on Tuesday . The stock traded as low as $90.16 and last traded at $90.67. Approximately 130,921 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 204,104 shares. The stock had previously closed at $96.29.Wall Street Analyst Weigh InA number of analysts recently commented on BLLN shares. Wells Fargo & Company started coverage on Billiontoone in a report on Monday, December 1st. They set an "equal weight" rating and a $110.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Billiontoone from $150.00 to $145.00 and set an "overweight" rating for the company in a report on Wednesday, December 10th. Zacks Research upgraded Billiontoone to a "hold" rating in a research note on Tuesday, December 2nd. Wall Street Zen raised Billiontoone to a "hold" rating in a report on Saturday, November 15th. Finally, BTIG Research restated a "buy" rating and issued a $160.00 price objective on shares of Billiontoone in a research report on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $137.83.Check Out Our Latest Research Report on BLLNBilliontoone Stock Down 6.4%Billiontoone (NASDAQ:BLLN - Get Free Report) last announced its quarterly earnings data on Tuesday, December 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.06). The firm had revenue of $83.52 million during the quarter, compared to analysts' expectations of $82.86 million. Billiontoone Company Profile (Get Free Report)BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical. BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.Featured StoriesFive stocks we like better than BilliontooneDo not delete, read immediatelyElon Warns “America Is Broke”. Trump’s Plan Inside.INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffCan Any Expenses Be Deducted From Capital Gains Tax?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Billiontoone Right Now?Before you consider Billiontoone, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Billiontoone wasn't on the list.While Billiontoone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here